Mitchell Chan - 06 Jan 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role: Chief Financial Officer
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol: RGNX
Transactions as of: 06 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 08 Jan 2026, 16:33:39 UTC
Previous filing: 03 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Chan Mitchell	Chief Financial Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE	/s/ Patrick J. Christmas as attorney-in-fact	08 Jan 2026	0001789335

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGNX	Common Stock	Award	$0	+73,749	+137%	$0.000000	127,717	06 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGNX	Stock Options (Right to buy)	Award	$0	+39,650		$0.000000	39,650	06 Jan 2026	Common Stock	39,650	$14.18	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.
F2	25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.